Drugs / ADA-011
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05601219 | Nov 2022 → Oct 2024 | cancer | Adanate, Inc | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ADA-011 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05601219 ↗ |
| Modality | Monoclonal antibody | — CHEMBL6068567 ↗ |
| Route | Intravenous | “administered intravenously (IV)” NCT05601219 ↗ |